ストックスクリーナーアプリを入手
3.13
6.01%
-0.20
プレマーケット:
3.21
0.08
+2.56%
前日終値:
$3.33
開ける：
$3.28
24時間の取引高:
1.13M
Relative Volume:
2.07
時価総額：
$975.31M
収益：
$548.10M
当期純損益:
$69.50M
株価収益率:
13.59
EPS:
0.2303
ネットキャッシュフロー:
$-137.90M
1週間 パフォーマンス:
-18.06%
1か月 パフォーマンス:
-23.84%
6か月 パフォーマンス:
-63.52%
1年 パフォーマンス:
-72.92%
1日の値動き範囲:
$3.03
$3.28
1週間の範囲:
$3.03
$3.848
52週間の値動き範囲:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.13 | 975.31M | 548.10M | 69.50M | -137.90M | 0.2303 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-11-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 開始されました | UBS | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Alvotech price target lowered to $4 from $8 at Deutsche Bank - TipRanks
Barclays Lowers Price Target for Alvotech (ALVO) to $4.00, Maint - GuruFocus
UBS cuts Alvotech stock price target on delayed biosimilar launches - Investing.com UK
Alvotech (ALVO) Maintains 'Buy' Rating with Lowered Price Target by UBS | ALVO Stock News - GuruFocus
UBS Group Cuts Alvotech (NASDAQ:ALVO) Price Target to $6.00 - MarketBeat
Barclays Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating - marketscreener.com
Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating - marketscreener.com
Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target - TipRanks
Alvotech SA stock hits 52-week low at $3.42 amid challenging year - Investing.com Canada
Barclays lowers Alvotech stock price target to $4 on approval timing - Investing.com India
Alvotech (NASDAQ:ALVO) Trading Down 5.1%Here's What Happened - MarketBeat
Alvotech price target lowered to $4 from $5 at Barclays - TipRanks
Northland Securities Weighs in on Alvotech FY2026 Earnings - MarketBeat
Operating cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Free cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Analyst Calls: Can Alvotech Equity Warrant maintain its current growth rateWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Alvotech Stock Faces Market Cap Decline Amid Biotech Sector Pressures in Early 2026 - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Upgraded by Zacks Research to Hold Rating - MarketBeat
Alvotech stock advances on biosimilar approvals and capacity expansion amid strong biotech momentum - AD HOC NEWS
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative? - Yahoo Finance
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles By Investing.com - Investing.com Canada
Alvotech (ALVO) TTM Profitability Challenged By Q4 US$108.5 Million Net Loss - simplywall.st
Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches - MSN
Alvotech (NASDAQ:ALVO) Hits New 1-Year LowShould You Sell? - MarketBeat
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles - Investing.com
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast By Investing.com - Investing.com Australia
ALVO: 2025 revenue rose 21% to $593M; 2026 guidance set at $650–$700M with strong pipeline momentum - TradingView
Alvotech Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast - Investing.com
Alvotech 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-03-19 - Seeking Alpha
Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands - TipRanks
Alvotech (NASDAQ: ALVO) turns profit as 2025 revenue rises 21% and sets 2026 growth targets - Stock Titan
Alvotech earnings beat by $0.11, revenue topped estimates - Investing.com India
Alvotech earnings beat by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech Q4 Revenue Increases; 2026 Revenue Guidance Issued - marketscreener.com
Alvotech Provides Updates on Launch & Regulatory Plans for Golimumab, High Dose Aflibercept, Vedolizumab and Pembrolizumab Biosimilars - Pearce IP
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance - ChartMill
Alvotech's Guidance Hike Sets Higher Bar for 2026 Growth Execution - Bitget
ALVOTECH ($ALVO) Releases Q4 2025 Earnings - Quiver Quantitative
Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments - Quiver Quantitative
Alvotech Q4 2025 and Full Year 2025 Financial Results - Caledonian Record
Alvotech expects four U.S. biosimilar approvals by late 2026 - Stock Titan
Alvotech’s fourth quarter results need to support the bearish outlook in order to shift the prevailing story - Bitget
Earnings Scheduled For March 18, 2026 - Benzinga
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Alvotech's Q4 Report: Regulatory Concerns for AVT05 Diminish Impact of Revenue Outperformance - Bitget
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
1.88%
大文字化:
|
ボリューム (24 時間):